Journal of Biomedical Science is supported by the National Science and Technology Council (NSTC), Taiwan.
Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
Chimeric antigen receptor (CAR)-T cell therapies have been approved by FDA to treat relapsed or refractory hematological malignancies. However, the adverse effects of CAR-T cell therapies are complex and can b...